Media coverage about DexCom (NASDAQ:DXCM) has been trending somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 45.2613649320193 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

DexCom (DXCM) traded up $1.56 on Friday, hitting $61.53. 2,116,764 shares of the company traded hands, compared to its average volume of 1,585,820. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom has a twelve month low of $42.62 and a twelve month high of $88.80.

DXCM has been the subject of a number of recent research reports. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reiterated a “buy” rating and set a $76.00 price target on shares of DexCom in a report on Wednesday, October 4th. Robert W. Baird reiterated a “hold” rating and set a $79.00 price target on shares of DexCom in a report on Sunday, September 10th. Finally, Barclays initiated coverage on shares of DexCom in a report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $70.69.

In related news, EVP Andrew K. Balo sold 6,490 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Barbara Kahn sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total transaction of $163,740.00. Following the completion of the sale, the director now directly owns 4,353 shares in the company, valued at $237,586.74. The disclosure for this sale can be found here. Insiders sold 37,954 shares of company stock worth $2,266,296 over the last three months. Corporate insiders own 1.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “DexCom (DXCM) Getting Somewhat Positive Media Coverage, Report Finds” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/11/dexcom-dxcm-getting-somewhat-positive-media-coverage-report-finds.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.